A human blood donor product made up of immunoglobulins (IgG and IgM antibodiesA protective protein produced by your immune system that attaches to antigens (foreign substances), such as bacteria and toxins, and removes them from your body. In myelin oligodendrocyte glycoproten antibody disease (MOGAD), the body incorrectly produces an antibody that targets myelin oligodendrocyte glycoprotein, a component of the myelin sheath in the central nervous system.) derived from plasma that can be administered intravenouslyA way of giving a drug or other substance through a needle or tube inserted into a vein. (IVIG) or subcutaneously (SCIG). For myelin oligodendrocyte glycoprotein antibody disease (MOGAD)Often referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease , it is used as an immunomodulatorA substance that affects the function of the immune system, either stimulating or suppressing its activity to reduce disease activity. Sometimes used for acuteThe severe and sudden onset of a disease process. attacks or as an ongoing preventativeRefers to a medication or treatment that is administered to prevent future relapses (Also referred to as Preventative or Preventive Treatment). treatment.
Related Posts
The MOG Project Applauds Results from the Hoffmann-La Roche & Genentech Clinical Trial
Results point to Enspryng® (satralizumab) as effective in blocking IL-6 receptor and MOGAD-related inflammationA process of the immune system that involves chemicals released by immune cells (i.e. white blood cells) inducing localized heat, swelling, redness, and pain to an area that occurs when tissue becomes damaged or infected from a pathogen, and usually results in the desctruction and removal of the pathogen and/or healing to the tissue. In the case of myelin oligodendrocyte glycoprotein antibody disease (MOGAD), inflammation is the result of the incorrect targeting of the myelin oligodendrocyte glycoprotein (MOG) by the immune system, resulting in damage to myelin sheaths. Washington, DC – (April 21, 2026) The MOG Project is thrilled
The MOG Project Awards 2025 Research Grants
The MOG Project’s Research for Rare program has awarded our 2025 MOGADOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease global research grants: the Apollo Grant and the Accelerator Grant. These grants are